With the hope that disease-modifying treatments could target the molecular basis of
Parkinson's disease, even before the onset of symptoms, we propose a biologically based …

Parkinson's disease and dementia with Lewy bodies are currently defined by their clinical
features, with α-synuclein pathology as the gold standard to establish the definitive …

Background Emerging evidence shows that α-synuclein seed amplification assays (SAAs)
have the potential to differentiate people with Parkinson's disease from healthy controls. We …

Abstract α-Synuclein aggregates constitute the pathology of Lewy body (LB) disease. Little is
known about the effects of LB pathology in preclinical (presymptomatic) individuals, either as …

Misfolded alpha-synuclein (αSyn) aggregates are a hallmark event in Parkinson's disease
(PD) and other synucleinopathies. Recently, αSyn seed amplification assays (αSyn-SAAs) …

Abstract Parkinson's disease (PD), the second most common progressive
neurodegenerative disease, develops and progresses for 10–15 years before the clinical …

Disease staging is an important tool in both clinical research and medical practice because
it allows for an unequivocal allocation of individuals into groups of shared biomedical …

Background Misfolded α‐synuclein (αSyn) aggregates (αSyn‐seeds) in cerebrospinal fluid
(CSF) are biomarkers for synucleinopathies such as Parkinson's disease (PD). αSyn‐seeds …

Parkinson disease (PD) is the second most common neurodegenerative disease, and the
most common synucleinopathy, as alpha-synuclein (α-syn), a prion-like protein, plays an …

The synuclein family includes three neuronal proteins, named α‐synuclein, β‐synuclein, and
γ‐synuclein, that have peculiar structural features. α‐synuclein is largely known for being a …